HMGB 1
Alternative Names: HMGB-1Latest Information Update: 28 May 2024
At a glance
- Originator 180 Life Sciences
- Class Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver disorders
Most Recent Events
- 22 Sep 2022 180 Life Sciences terminates licensing agreement with Oxford University for HMGB 1
- 20 Dec 2021 180 Life Sciences and University of Oxford enters into a licensing agreement for HMGB 1 for Liver disorders
- 15 Dec 2021 Preclinical trials in Liver disorders in United Kingdom and USA (unspecified route) before December 2021